International Trial Has Launched for Preterm Caffeine Dosing
Researchers are comparing three caffeine regimens for premature infants to determine the best approach for long-term health.
Updated on Oct. 14, 2026 in Babies
Live Poll
Do you believe clinical trials involving infant medical treatments are essential for improving long-term care?
The BabyCCINO study has launched an international clinical trial comparing three different caffeine dosing regimens for premature infants. This large-scale research involves 4,000 neonates across Australia, New Zealand, and the United Kingdom.
Why it matters
Current medical practices currently lack confirmed data on which caffeine dose provides the best long-term developmental outcomes for preterm babies. This study aims to standardize care by identifying the most effective and safe regimen to support breathing and growth.
The BabyCCINO study is the largest trial of its kind, comparing three distinct caffeine dosing levels in 4,000 premature infants. Researchers will measure growth and developmental outcomes in participants two to three years after hospital discharge.
The players
Mercy Hospital for Women
A Melbourne-based clinical site specializing in obstetric and neonatal care that is hosting the international trial.
The details
Caffeine is frequently used in neonatal intensive care to stimulate the brains of preterm babies, which helps support their respiratory function. The BabyCCINO study will evaluate health outcomes in hospital settings while testing three different dosing levels to identify which regimen offers the most effective support. Following discharge, researchers will conduct long-term growth and development assessments to track the children's progress over several years.
Timeline
The BabyCCINO study launched at Mercy Hospital for Women in Melbourne as of October 14, 2026.
Researchers will assess long-term growth and development 2 to 3 years after the infants are discharged.
Health Landscape
The BabyCCINO study represents a significant effort to establish evidence-based dosing standards for caffeine, a common intervention in neonatal intensive care. This trial aims to address existing gaps in medical guidelines to improve long-term outcomes for preterm infants worldwide.
Parents of premature infants may see shifts in neonatal care protocols as participating hospitals plan to implement findings immediately upon the trial's completion. If your child is in neonatal care, these evolving guidelines are worth discussing with your pediatrician or neonatologist.
The takeaway
This trial seeks to identify the safest and most effective caffeine dosages to support the long-term health of premature infants. Families with concerns about current neonatal treatment protocols should speak with their attending physician to understand how new clinical findings may affect care.
Further reading
For more information on the latest clinical research in neonatal development, visit the Babies section.
Live Poll
Do you believe clinical trials involving infant medical treatments are essential for improving long-term care?
